Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

Aims The immune response is essential for the control and resolution of viral infections.
Following the outbreak of novel coronavirus disease (COVID-19), several immunotherapies …

The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has become a global major concern. In this review, we addressed a theoretical …

The newfound coronavirus disease 2019 (COVID-19), initiated by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is an international public health concern …

COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising
infection rates, patient groups characterized by an enhanced infection risk will be …

Over the 2 months since coronavirus first appeared in China, cases have emerged on every
continent, and it is clear that patients with autoimmune diseases might also be affected …

The outbreak of coronavirus disease 2019 (COVID‐19) and pandemic, caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become a major concern …

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), has resulted in a pandemic that has had widespread …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …

Acute COVID-19, caused by SARS-CoV-2, is characterized by diverse clinical presentations,
ranging from asymptomatic infection to fatal respiratory failure, and often associated with …